MedTrace Logo

Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries

NCT00829296 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-02-05

Study results available
· View outcomes & findings →

Summary

The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.

Conditions

Interventions

DRUG

nebivolol

Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached

DRUG

Metoprolol

Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • George Bakris, M.D. · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829296 on ClinicalTrials.gov